Your skepticism is always appreciated. However, in the press release by MMTC, there is mention by executives of both companies of a sale of 5 systems this year. It will probably not be in the company’s sales revenue until the fourth quarter.
Mr. Ronald Tucker, EPIC's CEO, stated, "EPIC is preparing a program to purchase MIT's hardware and license MIT's software libraries that can currently detect, almost instantly, many different types of bacterium and believe that within the next year over thirty systems will be sold, generating in excess of $1 million in initial revenue to be followed by recurring software licensing fees, support agreements and sales of consumable products. As an additional reinforcement of our commitment to MIT we have also ordered five MIT 1000 Systems for immediate delivery in a transaction roughly valued at $200,000."
Mr. Michael Brennan, MIT's Chairman, said, "We are very appreciative of EPIC's initial order. Also, as previously stated, this agreement with EPIC will provide us with needed funding now that we have emerged from our development stage and a partner that is very familiar with the healthcare industry. This will enable MIT to approach other markets in healthcare in addition to our current exclusive focus on the $3.5 billion food safety segment."
News 
Market Data 
Discover 
